Ovine Placenta Extract (Ovis aries)

Ovine placenta extract, derived from sheep (Ovis aries) placental tissue, is a peptide-rich glandular supplement containing growth factors, cytokines, and bioactive proteins including insulin-like growth factor-1 (IGF-1) and epidermal growth factor (EGF). These compounds are proposed to support tissue repair and cellular regeneration by binding to membrane receptors that activate downstream proliferative signaling cascades.

Origin & History

Ovine placenta extract is derived from sheep (Ovis aries) placental tissue through enzymatic hydrolysis using proteases at controlled temperatures (43-45°C), followed by ultrafiltration and concentration. The final product contains peptide-rich compounds with molecular weights predominantly below 15,000 Da, obtained through mechanical processing and standardization methods.

Historical & Cultural Context

The research dossier does not contain information about traditional or historical use of ovine placenta extract in any traditional medicine systems. The duration and cultural context of traditional use cannot be determined from the available sources.

Health Benefits

• Limited evidence suggests potential effects on mammary tissue development (based on animal data showing 16.73% udder circumference increase)
• May influence lactation parameters (7.92% milk yield increase reported in animal studies)
• Peptide-rich composition theoretically supports tissue repair (no human clinical evidence available)
• Contains hydrolyzed proteins that may support general protein supplementation (mechanism not clinically validated)
• Potential cosmetic applications in topical formulations (based on patent documents, no clinical trials)

How It Works

Ovine placenta extract contains epidermal growth factor (EGF) and insulin-like growth factor-1 (IGF-1), which bind to their respective tyrosine kinase receptors (EGFR and IGF-1R), activating the PI3K/Akt and MAPK/ERK signaling pathways that regulate cell proliferation and differentiation. Prolactin-sensitizing peptides present in the extract may potentiate JAK2/STAT5 signaling in mammary epithelial cells, theoretically enhancing alveolar development and milk protein synthesis. Additionally, collagen precursor peptides and placenta-derived cytokines such as transforming growth factor-beta (TGF-β) may modulate extracellular matrix remodeling to support tissue repair.

Scientific Research

The available research is extremely limited, with only one study reporting effects on mammogenesis showing 7.92% milk yield increase and udder development measurements, though this appears to be animal rather than human data. No PubMed-indexed randomized controlled trials or meta-analyses evaluating ovine placenta extract in humans were found in the research dossier.

Clinical Summary

Current evidence for ovine placenta extract in humans is extremely limited, with most data originating from veterinary and animal model studies rather than controlled human clinical trials. Animal research has reported a 16.73% increase in udder circumference and a 7.92% increase in milk yield in treated livestock, suggesting genuine biological activity on mammary tissue, though direct extrapolation to human physiology is speculative. No large-scale, peer-reviewed, randomized controlled trials in humans have established standardized dosing, confirmed efficacy endpoints, or validated safety profiles for this extract as a dietary supplement. The evidence base is currently insufficient to support strong clinical claims, and effects observed in Ovis aries models may not translate meaningfully to human subjects.

Nutritional Profile

Ovine placenta extract is a protein-dense biological material with a complex composition reflecting its role as a nutrient-transfer organ. Crude protein content typically ranges from 60–80% on a dry weight basis, composed of hydrolyzed peptides and intact structural proteins including collagen (Type I, III, IV), fibronectin, laminin, and albumin fractions. Amino acid profile is notably rich in glycine (~11–14% of total amino acids), proline (~8–10%), hydroxyproline (~9%), glutamic acid (~7–9%), and arginine (~5–7%), mirroring connective tissue protein signatures. Bioactive peptide fractions (molecular weight <10 kDa) constitute approximately 15–30% of total protein content post-hydrolysis and are considered the primary functional components. Growth factor-associated proteins present include insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), and transforming growth factor-beta (TGF-β), though concentrations vary significantly by extraction method and processing temperature. Lipid content is low, approximately 3–8% dry weight, with phospholipids (phosphatidylcholine, phosphatidylserine) comprising the majority of the lipid fraction. Carbohydrate content is minimal (<5%), primarily as glycosaminoglycans including hyaluronic acid and heparan sulfate. Micronutrient content includes iron (estimated 2–5 mg/100g dry weight), zinc (~1–3 mg/100g), selenium (trace levels ~10–20 µg/100g), and B-vitamins including B12 (~0.5–2 µg/100g) and folate. Nucleotide fractions (DNA/RNA remnants) may be present depending on processing. Bioavailability is substantially influenced by hydrolysis degree; extensively hydrolyzed extracts yield di- and tripeptides with estimated intestinal absorption rates of 70–85%, while intact protein fractions face standard protease degradation limiting bioavailability of intact growth factors to negligible levels via oral route. Processing temperature above 60°C degrades heat-labile growth factor activity significantly.

Preparation & Dosage

No clinically studied human dosage ranges are available in the current research. Manufacturing specifications describe formulations containing 100 grams of extract powder per 1000-gram final product, but these represent industrial formulation ratios rather than therapeutic doses. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Insufficient research to recommend synergistic combinations

Safety & Interactions

Ovine placenta extract carries a theoretical risk of allergic or hypersensitivity reactions, particularly in individuals with known sensitivities to animal-derived proteins or lanolin-related compounds from sheep. Because the extract contains growth factors such as IGF-1 and EGF, individuals with hormone-sensitive conditions, including estrogen-receptor-positive cancers or active neoplasms, should avoid use due to potential mitogenic activity. Drug interactions are poorly characterized, but concurrent use with exogenous hormones, hormone modulators, or immunosuppressants warrants caution given the extract's cytokine and growth factor content. Safety during pregnancy and lactation in humans has not been established, and use during these periods is not recommended without explicit medical supervision.